Vandetanib inhibits signaling pathways activated by EGFRvIII, such as STAT3, AKT, and Bcl-xL, thus reducing cell growth and angiogenesis in glioma cell lines that express EGFRvIII [250]. Here, AKT1 is linked to central nervous system cancer.